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Background: Intussusception (IS) is a form of acute intestinal obstruction that occurs mainly in infants and is
usually of unknown cause. An association between IS and the first licensed rotavirus vaccine, a reassortant-
tetravalent, rhesus-based rotavirus vaccine (RRV-TV), led to the withdrawal of the vaccine. New rotavirus vaccines
have now been developed and extensively studied for their potential association with IS. This study aimed to
describe the epidemiology and to estimate the incidence of IS in Latin American infants prior to new vaccine
introduction.
Methods: Children under 2 years of age representing potential IS cases were enrolled in 16 centers in 11 Latin
American countries from January 2003 to May 2005. IS cases were classified as definite, probable, possible or
suspected as stated on the Brighton Collaboration Working Group guidelines.
Results: From 517 potential cases identified, 476 (92%) cases were classified as definite, 21 probable, 10 possible
and 10 suspected for intussusception. Among the 476 definite IS cases, the median age at presentation was
6.4 months with 89% of cases aged <1 year. The male to female ratio was 1.5:1. The incidence of definite IS per
100,000 subject-years ranged from 1.9 in Brazil to 62.4 in Argentina for children <2 years of age, and from 3.8 in
Brazil to 105.3 in Argentina for children aged <1 year. Median hospital stay was 4 days with a high prevalence of
surgery as the primary treatment (65%). Most cases (88%) made a complete recovery, but 13 (3%) died. No clear
seasonal pattern of IS cases emerged.
Conclusions: This study describes the epidemiology and estimates the incidence of IS in Latin American infants
prior to the introduction of new rotavirus vaccines. The incidence of IS was found to vary between different
countries, as observed in previous studies.
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Intussusception (IS) is a form of acute intestinal obstruc-
tion that occurs mainly in infants [1]. It is the most
frequent cause of acute abdominal emergency in the first
two years of life but rarely occurs in adults [1]. Most
cases of IS are considered idiopathic although several
authors have suggested links with various infectious
agents [2-4]. An association between natural rotavirus
(RV) infection and IS has not been found [3,5,6]. The
main argument against this association is the seasonality
of RV disease in children between 3–24 months without
any similar variability in IS prevalence in the same age
group [6-10].
The first RV vaccine licensed in the United States
(RotaShield™, Wyeth-Lederle) was withdrawn in 1999
because of concerns about the association of vaccination
with IS [11,12]. In retrospective investigations, adminis-
tration of this tetravalent rhesus human reassortant RV
vaccine (RRV-TV) was associated with a significantly in-
creased risk of IS (case–control analysis, adjusted odds
ratio: 21.7; 95% CI: 9.6 to 48.9), especially in the two
weeks following the first vaccination dose [5,13].
Development of a safe and effective RV vaccine has
been given high priority by the WHO because of the
considerable RV disease burden especially in developing
countries [14,15]. Newly licensed RV vaccines include a
human RV vaccine (HRV) (Rotarix™, GlaxoSmithKline
Vaccines) and a human-bovine reassortant vaccine
(RotaTeq™, Merck & Co.). Results of large-scale, ran-
domized, double blind, placebo-controlled studies, each
involving more than 60,000 infants, show these new RV
vaccines to be immunogenic and highly effective for the
prevention of RV gastroenteritis and associated hospitali-
zations during the first year of life. Importantly, both
vaccines appear to have a favorable safety profile, with
both studies excluding any immediate risk of IS (risk <1
in 20,000) [16,17].
Universal RV vaccination has been introduced in many
Latin American countries; since 2006, 14 countries and
one territory have incorporated vaccines in their National
Immunization Programs, including 12 countries using
Rotarix™ and 2 using RotaTeq™ [18]. Recent post-licensure
IS surveillance studies have associated rotavirus vacci-
nation with an increased, short-term risk of IS within
7 days following the first vaccine dose among Mexican
infants [19,20]. However, a recent analysis involving 14
Latin American countries using rotavirus vaccines pro-
vided evidence that health benefits of vaccination far
outweigh this transient risk and support continuous RV
vaccination in Latin America [21].
This study was conducted to provide an understanding
of the epidemiology and to estimate the incidence of IS in
Latin American infants prior to RV vaccine introduction.
Since there is a need for continuous safety surveillance incountries that have adopted RV vaccination into their
public sectors, our study will provide useful baseline IS
rates regarding further assessment of the potential IS risk
versus health benefits in Latin America.
Methods
Study design
This is a prospective, cross-sectional, observational study
conducted between January 2003 and May 2005 at 14 cen-
ters in Argentina, Brazil, Chile, Colombia, the Dominican
Republic, Honduras, Mexico, Nicaragua, and Panama. Dur-
ing the first year, the study was also conducted in 1 center
in Peru and 1 center in Costa Rica (16 centers in total).
Centers were selected by their importance as regional/na-
tional reference hospitals within the public health-care
system of the above mentioned countries, capacity to
perform surveillance for IS and their potential to participate
in a large safety and efficacy trial of RIX4414 vaccine
(Rotarix™, GlaxoSmithKline Vaccines, NCT00140673). The
surveillance ran in parallel to the safety and efficacy trial.
The study was approved by the following Institutional
Review Boards at all participating centers: Comité de Ética,
Hospital Humberto Noti (Argentina); Comitê de Ética
em Pesquisa, Instituto Evandro Chagas, FUNASA and
Comissão Nacional de Ética em Pesquisa (CONEP) (Brazil);
Comité de Ética Ad Hoc, Ministerio de Salud (Chile);
Unidad de Bioética e Investigación, Comité Ético Científico,
Hospital de Niños Dr. Carlos Saenz Herrera, Centro de
Ciencias Médicas CCSS (Costa Rica); Comité de Ética
en Investigación Biomédica de la Universidad Nacional
Autónoma de Honduras, Facultad de Ciencias Médicas
(Honduras); Centro de Investigación y Ética del Hospital
General de Tlanepantla (Mexico), Comité de Etica del
Hospital del Niño Morelense, Comité de Etica del Instituto
Nacional del Pediatría Insurgentes Sur, Comité de Ética e
Investigación del Hospital General de Durango and Comité
Local de Investigación y de Bioética Hospital General de
Pediatria (Mexico); Comité de Ética para Investigaciónes
Biomédicas, Universidad Nacional Autónoma de Nicaragua,
Facultad de Ciencias Médicas (Nicaragua); Instituto
Conmemorativo Gorgas de Estudios de la Salud Justo
Arosemena (Panama), Instituto Nacional de Salud (Peru),
Comité de Bioética, Hospital Maternidad Nuestra Señora
de Altagracia (Dominican Republic); and Comité de Etica
Clínica Materno Infantil Los Farallones (Colombia). The
study was conducted in accordance with the Declaration of
Helsinki, Good Clinical Practice guidelines and the Inter-
national guidelines for Ethical Review of Epidemiological
Studies. Written informed consent was obtained from the
parents/guardians of all children prior to enrolment.
Study population
Children receiving care for potential IS at participating
hospitals were identified by systematic reviews of hospital
Table 1 Major and minor criteria used in the case
definition for the diagnosis of intussusception
1. Evidence of intestinal obstruction: Predisposing factors:
I. History of bile-stained vomiting
and either
Age <1 year and male sex
II. Examination findings of acute
abdominal distension and abnormal
or absent bowel sounds
Abdominal pain
or Vomiting
III. Plain abdominal radiograph showing
fluid levels and dilated bowel loops.
Lethargy
2. Features of intestinal
invagination: One or more of the
following:
Pallor
I. Abdominal mass Hypovolemic shock;
III. Rectal mass Plain abdominal radiograph
showing an abnormal but
non-specific bowel gas patternIIII. Intestinal prolapse
IV. Plain abdominal radiograph showing
a visible intussusceptum or soft
tissue mass
V. Abdominal ultrasound showing a
visible intussusceptum or soft tissue
mass
VI. Abdominal CT scan showing a
visible intussusceptum or soft tissue
mass.
3. Evidence of intestinal vascular
compromise or venous congestion:
I. Passage of blood per rectum
or
II. Passage of a stool containing
“red currant jelly” material
or
III. Blood detected on rectal
examination
J.E. Bines http://www.sciencedirect.com/science/article/pii/
S0264410X03006637, K.S. Kohl, J. Forster, et al., Vaccine. 22 (2004) 569–574.
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gency department, pediatric ward, surgical department,
and radiology). A screening sheet was used in all appro-
priate departments to identify all eligible cases. Eligibility
criteria for the study were limited to: children under
24 months of age at onset of a potential IS episode; epi-
sodes that occurred during the study period; children for
whom consent could be obtained from a parent or guar-
dian; and children with no previous radiographically or
surgically confirmed IS episodes. When potential IS cases
that appeared to meet the eligibility criteria were iden-
tified, the child’s physician was asked for permission to
discuss the study with the child’s parents/guardians. If the
parents/guardians were interested in participation, written
informed consent was sought.
Data collection
Previous medical history, physical examination findings
on admission, radiographic and surgical procedures per-
formed, diagnosis, other treatments, pathologic findings,
duration of hospital stay, and outcome were entered into
a standardized data collection tool from medical chart
review and parental/guardian interview.
Case definition
IS cases were classified as definite, probable, possible or
suspected based on the Brighton Collaboration Working
Group guidelines [22,23]. According to these guidelines,
the evidence for definite IS requires a) the demonstration
of invagination of the intestine at surgery or b) by either
gas or liquid enema, or the demonstration of an intra-
abdominal mass by abdominal ultrasound with specific
characteristic features that is proven to be reduced by
hydrostatic enema on post-reduction ultrasound or c) the
demonstration of invagination of the intestine at autopsy.
If definite criteria is not fulfilled, cases were classified as
probable (2 major criteria or one major criteria and 3
minor criteria); possible (4 or more minor criteria), and
suspected IS represented by cases that did not meet any of
the three 3 levels of evidence (definite, probable, and
possible) (Table 1).
Data analysis
The complete analysis included all subjects enrolled
during the study duration. Following initial description
of identified cases, statistical analyses were limited to
definite IS cases.
For each country, the annual incidence of definite IS
was calculated with 95% confidence intervals (CI) for
children under 2 years and under 1 year of age. The
numerator was the number of cases of definite IS which
occurred in subjects living in the study area treated at a
participating hospital and enrolled in the study. Study
area denominators (the number of subjects living in thestudy area that would be expected to visit a participating
hospital if they developed suspected IS) were estimated
from national demographic statistics based on the most
recent national census. The study area was pre-defined
in accordance to the area of coverage of the participating
hospitals to the district level based on the political
division of the respective country. Analyses were perfor-
med using SAS® software (version 8.2).
Results
Study population
During the study period, 517 potential IS cases in
children under 2 years of age were identified. These were
classified as definite (n = 476; 92%), probable (n = 21;
4%), possible (n = 10; 2%), and suspected (n = 10; 2%).
Mexico had the highest number of definite IS case
reports (n = 113; 24%) (Figure 1). Other countries with
Figure 1 Enrolled definite IS cases by country and study area
residence (N = 476). During the study period, 517 potential IS cases
in children under 2 years of age were identified. Mexico had the
highest number of definite IS case reports (n = 113; 24%).
Figure 3 Monthly distribution of definite IS cases (overall and
in countries with >50 cases). Distribution of cases among months
of the year, no clear seasonal pattern of cases emerged either
overall or within individual countries with over 50 cases.
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(n = 57; 12%) and Panama (n = 55; 12%). Reports of male
cases were more common (gender ratio 1.5:1). The median
age of definite IS cases at presentation was 6.4 months.
Most cases (89%) occurred in the first year of life (Figure 2)
with a peak of cases between 4 and 8 months of age, and
the highest number of cases seen among children aged
5 months. No clear seasonal pattern of cases emerged
either overall or within individual countries with over 50
cases (Figure 3).
Definite IS incidence
When limited to definite IS cases who lived in the study
area (n = 385; 81%), the annual incidence of definite IS
for children under 2 years of age ranged from 1.9 per
100,000 subjects in Brazil to 62.4 per 100,000 subjects in
Argentina, with a wide variation in incidence. The
annual incidence of definite IS in children under 1 year
of age ranged from 3.8 per 100,000 subjects in Brazil to
105.3 per 100,000 subjects in Argentina, with a wide
variation in incidence (Figure 4).Figure 2 Overall age distribution of definite IS cases in Latin
American infants (N = 476). IS cases presentation, (89%) occurred
in the first year of life with a peak of cases between 4 and 8 months
of age, and the highest number of cases seen among children
aged 5 months.Clinical findings
The median hospital stay was 4 days (range 0–106 days).
The most common symptoms noted on admission of
definite IS cases were vomiting (91%), abdominal pain
(86%), and bloody stools (75%). Other commonly repor-
ted signs and symptoms included pallor (65%), abdo-
minal distension (60%), abnormal or absent bowel
sounds (56%), bile-stained vomiting (54%), red jelly stool
(54%), abdominal mass (51%), lethargy (50%), fever
(49%), and blood on rectal examination (48%); 92% of
cases presented with five or more symptoms.
Surgery was the most common primary treatment for
children with definite IS (308 [65%] primary surgeries).
Of the 168 children undergoing conservative primary treat-
ment (ultrasound-guided gas or liquid-contrast enema),
76 (45.5%) did not undergo secondary surgery. In most
(n = 66) of these cases an intra-abdominal mass with spe-
cific characteristic features, as reported in the Brighton
Collaboration Group guidelines, was exhibited by abdom-
inal ultrasound and proved to be reduced by hydrostaticFigure 4 Annual incidence of definite IS in children under
1 year of age per 100,000 subjects. Lines indicate 95% confidence
intervals. Figure shows that annual incidence of definite IS in
children under 1 year of age ranged from 3.8 per 100,000 subjects in
Brazil to 105.3 per 100,000 subjects in Argentina, with a wide
variation in incidence.
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performed on 400 (84%) children with definite IS including
bowel resection in 99 (25%) cases. Invagination was identi-
fied in 84% of patients undergoing surgery with the most
common involvement being ileo-cecal (89%).
Known predisposing factors were found in only 21
cases (4.4%), Meckel’s diverticulum was present in 13
cases (2.7%) and appendicitis was identified in 8 cases
(1.7%) at the time of surgery. A total of 130 (27.3%)
subjects had an upper respiratory tract infection in the
2 weeks before the onset of definite IS. Sixty-three
subjects (13.2%) reported an illness other than upper
respiratory tract infection during this period of time.
The remaining 283 subjects (59.5%) did not report any
illness within the 2 weeks before onset of definite IS.
Laboratory findings
A stool sample was obtained from 99 (21%) of the defi-
nite IS cases. Various pathogens were tested for, yielding
15 positive results for: adenovirus (1 out of 3 tests),
rotavirus (4 out of 43 tests), Escherichia coli (6 out of 23
tests), Shigella (1 out of 22 tests), Cryptosporidium
(1 out of 2 tests), Entamoeba histolytica (1 out of 8 tests)
and other unspecified parasites (1 out of 6 tests). All 7
tests for Campylobacter and 21 tests for Salmonella were
negative.
Patient outcome
Of the 476 definite IS cases, 418 (87.8%) recovered
without sequelae, 42 (8.8%) recovered with sequelae, 13
(2.7%) died, and 3 (0.7%) were transferred to other
hospitals and were lost to follow-up.
Discussion
This study estimated the incidence of definite IS in
young children in 11 Latin American countries as 1.9 to
62.4 per 100,000 children under 2 years of age and 3.8
to 105.3 per 100,000 children under 1 year of age, with a
wide variation in incidence. The estimates for children
under 1 year of age are in a similar range to published
estimates from other regions, 38 per 100,000 in
Switzerland (study period: 2003–2006) [24], 65 per
100,000 in New Zealand (study period: 1998–2003) [10],
66 per 100,000 in the UK [25], 71 per 100,000 in
Denmark (study period: 1990–2001) [26] and 78–100
per 100,000 in Hong Kong (study period: 1997–1999).
[8] However, the increase in definite IS incidence in the
second 6 months of life seen in other studies [24,26-28],
was not demonstrated in this study.
Our estimated IS incidence rates were similar to those
previously reported from this region. In a 5-year re-
trospective study in Panama (study period: 1998–2002),
annual rates of 19 to 40 cases of IS per 100,000 children
under 1 year of age, and 8 to 15 per 100,000 in childrenunder 3 years of age were reported depending on the
year of the study [29]. A study in Chile estimated the an-
nual IS rates in children under 1 year and under 2 years
of age to be 47–55 per 100,000 and 32–35 per 100,000,
respectively [30]. A study conducted in Venezuela repor-
ted an annual IS-related hospitalization rate of 35 per
100,000 in infants under 1 year of age [31]. In Brazil,
where this study showed the lowest incidences of defi-
nite IS despite case identification efforts that were
equally intensive as those in other participating coun-
tries, the World Health Organization has reported
similarly low annual incidence (3.5 per 100,000 children
under 1 year of age) [32]. There seems to be no clear
explanations for the variability in observed IS rates
between different Latin American countries, although
intussusception incidence can vary by region [32].
Country-specific incidence rates do not seem to suggest
ethnic or geographic influences (e.g. a North–south gra-
dient). While differences in healthcare access and patient
management (i.e., in some areas IS cases could not have
been seen by medical personnel) are likely to play a role,
other unknown factors that may be linked to IS, such as
genetic influence, cultural differences, infectious diseases
and gastrointestinal infections, may also be involved
[11,33-35]. It should be pointed out however that, when
defining specific catchment areas, it was assumed that
most of potential IS cases would reach the sentinel
hospitals for proper treatment, where intensive, daily
surveillance was carried out. It is however recognized
that less control could be exerted over cases that might
come from outside the study areas.
We found a relatively high proportion of subjects
(27.3%) who experienced IS to have had an upper respi-
ratory tract infection in the 2 weeks before the onset of
definite IS. The condition is known to be associated with
a number of childhood viral illnesses [33], in particular
with adenovirus [34], and a link with respiratory syncyt-
ial virus (RSV) infection has recently been reported [35].
The epidemiologic characteristics of definite IS cases
in this study were similar to those found in other
locations or previously in these countries. The majority
of definite IS cases occurred before 1 year of age with a
peak around 4–6 months of age, which is similar to
that observed in the US [36] and other countries
[24,25,29,30]. The excess of male cases has been noted
in other studies with male:female ratios of 1.8:1 and
1.4:1 reported from Panama and the US, respectively
[29,36].
The proportion of children undergoing surgery in the
present study (84%) was similar to other Latin American
studies, which have reported rates of 78% and 88% in
Chile and Venezuela, respectively [30,31,37]. However,
these rates are much higher than those reported from
Hong Kong (23%) and the US (53%) [8,9]. Higher
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seeking medical attention, more severe episodes, or less
experience in radiological reduction techniques. More-
over, it seems likely that IS cases that resolved sponta-
neously were not included, thus possibly leading to an
underestimate of the overall rate. The typical clinical
presentation (vomiting, pain or irritability, and bloody
stools) found in this study is similar to other reports as
was the low rate of predisposing conditions, such as
Meckel’s diverticulum [30-32,38]. Of interest, among the
465 subjects for whom the type of vaccine previously
administered was known, 27 (5.8%) had received human
rotavirus vaccine or placebo because they were partici-
pating in an ongoing phase III clinical trial in Latin
America. Nevertheless, it seems very unlikely that such a
low percentage might have influenced our overall
estimates for the occurrence of IS prior to vaccine
introduction.
The present study, like several others including some
from Latin America, showed no clear seasonality of
IS-associated hospitalisations [6,29,31]. The distribution
of definite IS cases did not correspond with the season-
ality of RV in any of these countries. As in other regions,
the occurrence of RV is higher in winter months in Latin
America, however, the timing and duration varies by
geographical location with peaks generally occurring in
Mexico between November and April [6,39], in Argentina
between April and August, in Brazil between May and
July, and in Chile between June and September [40,41].
We acknowledge the potential limitations of our study.
To estimate the incidence rates, we relied on census data
as denominators. The reliability of these census data is
variable. Whereas these data may be valid on national or
regional levels, they may be less precise for smaller
regions such as those that defined the catchment areas
for some centers. It is likely that this uncertainty ac-
counts for some of the difference between the estimated
incidence rates in different countries. We excluded
children who lived outside the defined study areas. How-
ever, study area boundaries may not have had the same
level of precision for all hospitals, which could affect the
incidence rates presented. It is therefore likely that some
cases of definite IS may have been referred to sentinel
hospitals from neighborhood localities that were sur-
rounding the originally defined study area. Also, in most
countries, the study took place in a limited number of
regional/national reference hospitals and therefore the
incidence rates for each country cannot be regarded as
national estimates.
It is possible that some of the cases that occurred in
the population counted as denominator may have been
treated in another hospital not involved in the study, in
particular private institutions. Although a systematic
review of private institutions within the study area wasalso performed during the surveillance and efficacy trial.
To ensure that the study procedures conformed across
all investigator centers add to limit potential under-
reporting, the study protocol, case report form and
safety reporting were reviewed with all investigators and
other personnel responsible for the conduct of the study
prior to study start and at regular interval periods.
Adherence to the protocol requirements and verification
of data generation accuracy was achieved through
monitoring visits to each investigator site. Furthermore,
computer checks and blinded review of subject tabu-
lations were performed to ensure consistency of case
report form completion. Finally, some parents (n = 22)
refused participation. As we did not know the age of
these children, we could not adjust our incidence rates
to account for these children, which may have resulted
in an underestimation.
Conclusions
Our findings are in line with previously reported figures
and suggest substantial variation in the rates of IS across
Latin America. This study provides a recent estimate of
the incidence of IS in Latin American infants, which is
helpful in monitoring the safety of new RV vaccines
following their introduction in the region. A few of these
previously foreseen post-licensure evaluations have re-
cently detected a transient, 4 to 6-fold increased relative
risk of IS within 7 days following first rotavirus vaccine
dose in Mexico. Nevertheless, recent estimates have
shown that hospitalisations and deaths averted as a result
of vaccination far outweigh the number of possible
vaccine-related IS cases and health authorities still con-
tinue to strongly recommend routine rotavirus vaccination
of infants in Latin America.
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